About Implant Therapeutics
Implant Therapeutics Offers
Hypoimmunogenic and safe harbor engineered IPSC derived cells for:
- Bioproduction
- Feeder lines and manufacturing
- Ex-vivo gene therapy
- Autologous transplant therapy
- Allogeneic transplant therapy
- Autologous or Allogeneic cancer therapy
- Tolerization and vaccination
Why Implant Therapeutics
IPSC-MSC offer cells with the same characteristics as adult derived cells with two advantages:
- Ability to gene edit
- Ability to make true hypoimmunogeneic cells in a scalable way
The ability to make hypoimmunogenic cells make IPSC MSC the choice for bone, cartilage and tendon replacement strategies combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles.
Implant Therapeutics combines the advantages of iPSC-MSC with panCELLa’s exclusive safety platforms to deliver the ultimate therapeutic MSC products.
Experience the Difference
Implant Therapeutic Services
- Cells/Cell lines for bioproduction uses including exosome manufacture
- iPSC derived MSC unmodified for therapy (eg: GVH, ARDS)
- iPSC derived MSC modified with a safe harbor site for over expression of antigen, missing factor or antibody delivery, etc.
- Cloaked or Hypoimmunogenic iPSC derived MSC differentiated into bone or cartilage for repair
- iPSC derived MSC for composite tissue and organoids
- HLA null MSC for a variety of additional uses – (eg feeder cells for NK and HSC manufacture)
- Cells for vaccine therapy including antigens and antibodies
Licensing
If you are interested in learning more about our technology, please complete the attached non-disclosure agreement ImplantMUTUAL_NDA_HIGHLIGHTED and remit via email Implantrx.ceo@gmail.com
News
Comprehensive Research & Technology Agreement signed with Angios Biotech and panCELLa.
Our companies are committed to providing the highest quality of cells for therapy. Mahendra Rao, CEO of panCELLa and founder of Implant, notes: “the collaboration of Angios with panCELLa and Implant brings together experts, across two continents, on pluripotent stem cells, gene editing and cell differentiation to treat diseases that require vascular reconstitution. [To read the full story click here]
Accelerating cell-based therapies by providing safe therapeutic MSC products.
Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering iPSC-MSC cells containing panCELLa’s FailSafeTM and induced Allogeneic Cell Tolerance (iACT Stealth CellTM) technologies. These iPSC MSC cells are hypo-immunogenic and are an ideal choice for bone, cartilage and tendon replacement strategies combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles. [To read the full press release click here]